Gilead Sciences: Leukemia trials

The registry lists 34 Leukemia studies with Gilead Sciences as lead sponsor. 0 are open to participants now and 22 have results posted.

Phase 1 16Phase 2 12Phase 3 8Phase 4 1No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid LeukemiaTerminatedNCT05079230Phase 3Results posted
• Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been TreatedTerminatedNCT04778397Phase 3Results posted
• Study to Evaluate the Safety and Tolerability of Brexucabtagene Autoleucel (KTE-X19) in People With Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic LymphomaTerminatedNCT03624036Phase 1Results posted
• Entospletinib (ENTO) as Monotherapy and in Combination With Chemotherapy in Japanese AdultsTerminatedNCT03135028Phase 1Results posted
• Safety and Efficacy of the Combination of Tirabrutinib and Entospletinib With and Without Obinutuzumab in Adults With Chronic Lymphocytic Leukemia (CLL)CompletedNCT02983617Phase 2Results posted
• Study to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib and Idelalisib With and Without Obinutuzumab in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)CompletedNCT02968563Phase 2Results posted
• A Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel (KTE-X19) in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ZUMA-3)CompletedNCT02614066Phase 1/2Results posted
• Study of Idelalisib in Combination With BI 836826 in Participants With Chronic Lymphocytic LeukemiaTerminatedNCT02538614Phase 1Results posted
• Safety and Efficacy of Entospletinib With Vincristine and Dexamethasone in Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)TerminatedNCT02404220Phase 1/2Results posted
• Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML)TerminatedNCT02343939Phase 1/2Results posted
• Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Participants With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas (iNHL) or Chronic Lymphocytic Leukemia (CLL)CompletedNCT02242045Phase 1Results posted
• Efficacy and Safety of Idelalisib in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia With 17p DeletionTerminatedNCT02044822Phase 2Results posted
• Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Adults With Previously Untreated Chronic Lymphocytic LeukemiaTerminatedNCT01980888Phase 3Results posted
• Efficacy and Safety of Idelalisib in Combination With Obinutuzumab Compared to Chlorambucil in Combination With Obinutuzumab for Previously Untreated Chronic Lymphocytic LeukemiaTerminatedNCT01980875Phase 3Results posted
• Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic MalignanciesTerminatedNCT01796470Phase 2Results posted
• Study to Evaluate the Safety and Tolerability of Tirabrutinib (ONO/GS-4059) Given as Monotherapy in Participants With Relapsed/Refractory NHL and CLLCompletedNCT01659255Phase 1Results posted
• Efficacy and Safety of Idelalisib in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic LeukemiaTerminatedNCT01659021Phase 3Results posted
• Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) (Tugela )CompletedNCT01569295Phase 3Results posted
• A Randomized, Double-Blind, Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)CompletedNCT01539512Phase 3Results posted
• Extension Study of Idelalisib in Participants With Chronic Lymphocytic Leukemia (CLL) Who Participated in GS-US-312-0116 (NCT01539512)TerminatedNCT01539291Phase 3Results posted
• A Study of Idelalisib and Rituximab in Elderly Patients With Untreated CLL or SLLTerminatedNCT01203930Phase 2Results posted
• Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic LeukemiaCompletedNCT01088048Phase 1Results posted
• US Expanded Access Program for Magrolimab in Patients With Relapsed or Refractory Acute Myeloid LeukemiaNo longer availableNCT05627466
• Clinical Outcomes and Routine Management of Adults With Chronic Lymphocytic Leukaemia Treated With Idelalisib and Rituximab in the United Kingdom (UK) and IrelandCompletedNCT03582098
• Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of GS-9901 in Adults With Relapsed or Refractory Follicular Lymphoma, Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic LymphomaTerminatedNCT02258555Phase 1
• Expanded Access for Idelalisib in Combination With Rituximab in Chronic Lymphocytic LeukemiaApproved for marketingNCT02136511
• Phase I Dose Escalation Study of IMMU-114 in Relapsed or Refractory NHL and CLLTerminatedNCT01728207Phase 1
• Phase I Study of Milatuzumab for Graft Versus Host DiseaseTerminatedNCT01663766Phase 1
• A Phase 2, Single-Arm, Open-Label Study Evaluating the Efficacy and Safety of Single Agent GS 1101 (CAL 101) as Therapy for Previously Treated Chronic Lymphocytic LeukemiaWithdrawnNCT01659047Phase 2
• Phase I/II Study of hLL1-DOX in Relapsed NHL and CLLTerminatedNCT01585688Phase 1/2
• Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic MalignanciesCompletedNCT00710528Phase 1
• Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLLCompletedNCT00546793Phase 1/2
• A Trial of GS-9219 in Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM)TerminatedNCT00499239Phase 1/2
• PROPHYSOME: Pilot Study on Safety of a Weekly Administration of 10mg/kg of AmBisome® in Antifungal Prophylaxis Treatment of Allogeneic Stem-cell Transplantation and Acute LeukaemiaCompletedNCT00362544Phase 4